Autoantibodies in laryngeal cancer: detection and role as a biomarker
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Autoantibodies (AAb) show potential as early diagnostic biomarkers for laryngeal cancer (LC). Higher AAb levels were found in LC patients, with good diagnostic performance independent of cancer stage.
Area Of Science
- Oncology
- Immunology
- Biomarker Discovery
Background
- The diagnostic role of autoantibodies (AAb) as serological biomarkers for laryngeal cancer (LC) has not been previously investigated.
- Early diagnosis of LC is crucial for improving patient outcomes.
Purpose Of The Study
- To investigate the presence of anti-LC autoantibodies (AAb) in laryngeal cancer patients.
- To evaluate the potential of anti-LC AAb as a biomarker for early LC diagnosis.
Main Methods
- Indirect enzyme-linked immunosorbent assay (ELISA) was used to measure anti-LC AAb levels.
- AAb levels were compared between 30 LC patients and 30 healthy individuals.
- Analysis included correlation with clinical factors such as tumor stage.
Main Results
- Significantly higher AAb levels were observed in LC patients compared to the control group (P = .019).
- Diagnostic performance metrics (sensitivity, specificity, PPV, NPV, accuracy) were 70% for AAb-level testing.
- AAb levels were not associated with cancer stage, symptom duration, or risk-factor exposure.
Conclusions
- A significant level of autoantibodies can be detected in laryngeal cancer patients.
- Anti-LC autoantibodies demonstrate good diagnostic performance, irrespective of cancer stage.
- These findings suggest anti-LC AAb hold potential as predictive biomarkers for early laryngeal cancer detection.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
